Mumbai, July 14, 2026: Global pharma major Lupin Limited (Lupin) today announced that it has been recognized among India's Best Employers in the Nation Builders Category 2026 by Great Place To Work® India, ranking among the Top 14 organizations nationally. This recognition reflects Lupin's enduring commitment to fostering a culture based on purpose, trust, and inclusion, while contributing to nation-building by expanding access to healthcare, advancing community development, and driving meaningful societal impact.
The Nation Builders category recognizes organizations whose impact extends beyond business performance through their contribution to employment, people development, community advancement and nation-building, while fostering exceptional workplace cultures.
Speaking on the occasion, Yashwant Mahadik, President – Global Human Resources, Lupin, said, "We are honored by this recognition, which celebrates the culture our people bring to life every day. At Lupin, we are focused on creating an environment where individuals feel supported, empowered, and connected to a shared purpose. By investing in our people and their growth, we are building a workplace that enables meaningful contributions to patients, communities, and society."
Organizations featured in this category are evaluated through a rigorous, independent assessment conducted by Great Place To Work® India. The selection is based on the Trust Index™, which considers employee experience, Culture Audit™ evaluations of people practices, and eligibility criteria that assess an organization's broader contribution to nation-building.
Through its people-first philosophy and unwavering focus on improving patient lives, Lupin continues to create value that extends well beyond business performance.
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 26,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn at https://www.linkedin.com/company/lupin
For further information or queries, please contact
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com
